Affinage

EP300

Histone acetyltransferase p300 · UniProt Q09472

Round 2 corrected
Length
2414 aa
Mass
264.2 kDa
Annotated
2026-04-28
130 papers in source corpus 55 papers cited in narrative 55 extracted findings

Mechanistic narrative

Synthesis pass · prose summary of the discoveries below

EP300 (p300) is a lysine acetyltransferase and transcriptional coactivator that acetylates all four core histones and a broad array of non-histone substrates—including p53, NF-κB RelA, MyoD, tau, RORγt, AFF1, and PCNA—thereby regulating transcription, DNA repair, cell-cycle progression, and protein stability (PMID:8945521, PMID:9288740, PMID:11533489, PMID:10944526, PMID:24939902, PMID:31611376). Beyond acetylation, p300 catalyzes histone crotonylation and 2-hydroxyisobutyrylation, linking metabolic acyl-CoA availability to chromatin state and glycolysis (PMID:25818647, PMID:29775581, PMID:39080296). Catalytic activation requires transcription-factor-dimerization-induced trans-autoacetylation of an intrinsically disordered autoinhibitory loop, with structural relief of RING-domain autoinhibition, and is further tuned by mTORC1 phosphorylation, AMPK-dependent nucleocytoplasmic shuttling, and HDAC8-mediated deacetylation (PMID:30323286, PMID:29033323, PMID:38267537, PMID:38030596). p300 also possesses a cytoplasmic E4 ubiquitin-ligase activity toward p53, and its chromatin engagement depends on combinatorial, multivalent interactions with multiple transcription factors through distinct TF-binding domains (PMID:19805293, PMID:38159566).

Mechanistic history

Synthesis pass · year-by-year structured walk · 15 steps
  1. 1994 High

    Molecular cloning of p300 established its identity as a bromodomain-containing transcriptional adaptor that could overcome E1A-mediated repression, framing all subsequent studies of its coactivator function.

    Evidence cDNA cloning with domain mapping and SV40 reporter assays

    PMID:7523245

    Open questions at the time
    • Enzymatic activity unknown at this stage
    • Mechanism of coactivation not defined
  2. 1996 High

    Demonstration that p300 possesses intrinsic histone acetyltransferase activity on nucleosomal substrates resolved how it activates transcription and defined it as a novel class of HAT distinct from GCN5-family enzymes.

    Evidence In vitro acetyltransferase assay with recombinant p300 and nucleosomes

    PMID:8945521

    Open questions at the time
    • Non-histone substrate scope unknown
    • Catalytic mechanism and regulation not resolved
  3. 1997 High

    Identification of p53 Lys-382 as the first non-histone acetylation substrate of p300 revealed that p300 functions beyond chromatin, directly modulating transcription factor DNA-binding and activity, and established a phosphorylation-acetylation signaling cascade for p53 activation.

    Evidence In vitro acetyltransferase assay, mutagenesis, EMSA, in vivo UV/IR-induced acetylation

    PMID:9288740 PMID:9744860

    Open questions at the time
    • Full spectrum of non-histone substrates unknown
    • Structural basis of substrate recognition undetermined
  4. 1997 High

    A series of studies showing p300 binds diverse transcription factors—p53, Smad1-4, C/EBPβ, MyoD, ER—and mediates their cooperative transcriptional activation established p300 as a universal scaffold integrating multiple signaling pathways at promoters and enhancers.

    Evidence Co-IP, E1A mutant epistasis, domain mapping, and reporter assays across multiple TF systems

    PMID:8876171 PMID:9194565 PMID:9343424 PMID:9659901 PMID:9722503

    Open questions at the time
    • Structural basis for simultaneous multi-TF engagement unknown
    • In vivo stoichiometry of complexes not established
  5. 1999 High

    The finding that p300 bridges STAT3 and Smad1 to drive astrocyte differentiation demonstrated that p300 integrates two distinct signaling pathways (LIF and BMP2) into a single transcriptional output, extending its scaffold function to developmental cell-fate decisions.

    Evidence Co-IP with domain mapping and neural progenitor differentiation assay

    PMID:10205054

    Open questions at the time
    • Whether p300 HAT activity is required for this bridging was not tested
    • Genome-wide target genes of the trimeric complex not identified
  6. 2000 High

    p300-mediated acetylation of MyoD was shown to be required for its transcriptional activity on muscle-specific promoters, and pharmacological/genetic inhibition of p300 HAT activity blocked myogenic differentiation, proving that the enzymatic activity—not just scaffolding—is essential for lineage commitment.

    Evidence In vitro acetylation, site-directed mutagenesis, HAT inhibitor and dominant-negative mutant in differentiation assays

    PMID:10944526 PMID:11073990 PMID:11726517

    Open questions at the time
    • Specific acetylation sites on MyoD necessary in vivo not fully mapped
    • Relative contribution of p300 vs. PCAF HAT activity not fully deconvolved
  7. 2001 High

    Acetylation of NF-κB RelA by p300 was found to weaken IκBα binding, while HDAC3-mediated deacetylation restored it, revealing a reversible acetylation switch that controls the duration of NF-κB nuclear residence and transcriptional responses.

    Evidence In vitro acetylation, Co-IP, nuclear export assays, reporter assays

    PMID:11533489 PMID:11931769

    Open questions at the time
    • Specific acetylated lysine residues on RelA responsible for the switch not fully defined in these studies
    • In vivo kinetics of the acetylation cycle not measured
  8. 2002 High

    Discovery that asparagine hydroxylation of HIF-α by FIH-1 blocks its interaction with p300 under normoxia revealed an oxygen-sensing mechanism that gates p300 recruitment, explaining how hypoxia activates HIF target genes.

    Evidence In vitro hydroxylase assay, mutagenesis, Co-IP, reporter assays

    PMID:11823643 PMID:12080085

    Open questions at the time
    • Whether p300 acetylates HIF-α directly was not determined
    • Structural basis of hydroxylation-dependent disruption not resolved at that time
  9. 2008 High

    An ENU-induced KIX domain mutation (Y630N) that disrupts p300–c-Myb interaction caused thrombocytosis and megakaryocyte expansion in mice, providing the first in vivo genetic evidence that a specific p300 protein-interaction domain controls a defined developmental program.

    Evidence ENU mutagenesis screen, bone marrow transplantation, interaction assays in mice

    PMID:18684867

    Open questions at the time
    • Whether the phenotype involves loss of c-Myb acetylation or only scaffolding was not distinguished
    • KIX domain interactions with other partners not comprehensively assessed
  10. 2009 High

    Identification of p300/CBP as cytoplasmic E4 ubiquitin ligases for p53 demonstrated a non-nuclear, non-acetyltransferase catalytic activity, showing that p300 exerts compartment-specific dual enzymatic functions—acetyltransferase in the nucleus and ubiquitin ligase in the cytoplasm.

    Evidence Cell fractionation, in vitro ubiquitin ligase assay, domain deletion analysis

    PMID:19805293

    Open questions at the time
    • Whether other cytoplasmic E4 substrates exist is unknown
    • Structural basis for E4 activity not resolved
  11. 2015 High

    Discovery that p300 catalyzes histone crotonylation in addition to acetylation, with crotonylation being a stronger transcriptional activator, expanded p300's enzymatic repertoire beyond a single acyl modification and linked metabolic acyl-CoA pools to epigenomic regulation.

    Evidence In vitro crotonyltransferase assay, metabolic perturbation, ChIP-seq, gene expression analysis

    PMID:25818647

    Open questions at the time
    • Genomic specificity of crotonylation vs. acetylation not fully defined
    • Reader proteins for crotonylation marks not identified in this study
  12. 2017 High

    Two studies revealed that mTORC1 phosphorylates p300's C-terminal serines to relieve RING-domain autoinhibition (activating acetyltransferase activity and suppressing autophagy), while p300 also functions as a 2-hydroxyisobutyryltransferase targeting glycolytic enzymes—together placing p300 at the nexus of nutrient sensing, metabolism, and chromatin regulation.

    Evidence In vitro kinase assay, domain interaction assay, proteomics, p300 KO cells, metabolic assays

    PMID:29033323 PMID:29775581

    Open questions at the time
    • Whether RING autoinhibition relief also controls non-acetylation acylation activities is unknown
    • In vivo metabolic consequences of Khib loss not fully characterized
  13. 2018 High

    Crystal structures and biochemical studies showed that transcription factor dimerization triggers trans-autoacetylation of p300's intrinsically disordered autoinhibitory loop, providing the first structural mechanism for how TF binding allosterically activates p300 catalysis.

    Evidence Crystal structure, in vitro autoacetylation assay, mutagenesis

    PMID:30323286

    Open questions at the time
    • Dynamics of autoinhibitory loop acetylation/deacetylation cycling in vivo not measured
    • Whether all TF-induced activation proceeds through this mechanism is unclear
  14. 2023 High

    Cryo-EM structures of p300 on nucleosomes revealed a read-write mechanism in which the bromodomain reads H4 tail acetylation and directs catalytic activity to non-H4 tails (primarily H2B), while single-molecule live-cell imaging showed that chromatin binding requires combinatorial engagement of multiple TF-interaction domains, explaining how p300 integrates diverse signals at enhancers.

    Evidence Cryo-EM structure, in vitro acetyltransferase/remodeling assays, single-molecule tracking with systematic domain mutagenesis

    PMID:37460559 PMID:38159566

    Open questions at the time
    • How the read-write mechanism operates on different chromatin states in vivo is incompletely characterized
    • Quantitative contribution of each TF-binding domain to residence time not resolved
  15. 2024 High

    AMPK-dependent phosphorylation at Ser89 was shown to drive p300 nuclear retention during nutrient depletion, while PP2A-mediated dephosphorylation enables CRM1-dependent nuclear export upon refeeding, establishing a nutrient-responsive nucleocytoplasmic shuttle that coordinates mTORC1 activity and autophagy; progerin-induced mislocalization of p300 in Hutchinson-Gilford progeria causes mTORC1 hyperactivation.

    Evidence Live-cell imaging, kinase/phosphatase inhibitors, CRM1 inhibition, progeria patient fibroblasts

    PMID:38267537

    Open questions at the time
    • Whether nucleocytoplasmic shuttling regulates p300's E4 ubiquitin ligase activity is untested
    • Therapeutic potential of correcting p300 localization in progeria not evaluated

Open questions

Synthesis pass · forward-looking unresolved questions
  • Key unresolved questions include: the structural basis for how p300 selects among its diverse acyl-CoA donors at specific genomic loci, the full scope and physiological significance of the cytoplasmic E4 ubiquitin ligase activity, and how p300 and CBP achieve non-redundant gene-specific functions despite high sequence homology.
  • No structure of p300 bound to non-acetyl acyl-CoA donors
  • Complete catalog of cytoplasmic E4 substrates unknown
  • Molecular determinants distinguishing p300- from CBP-specific enhancer targets remain unclear

Mechanism profile

Synthesis pass · controlled-vocabulary classification · explore literature graph →
Molecular activity
GO:0140096 catalytic activity, acting on a protein 16 GO:0140110 transcription regulator activity 9 GO:0016740 transferase activity 6 GO:0042393 histone binding 4 GO:0016874 ligase activity 1
Localization
GO:0005634 nucleus 5 GO:0005654 nucleoplasm 3 GO:0005829 cytosol 3
Pathway
R-HSA-74160 Gene expression (Transcription) 9 R-HSA-162582 Signal Transduction 7 R-HSA-4839726 Chromatin organization 7 R-HSA-1266738 Developmental Biology 4 R-HSA-5357801 Programmed Cell Death 3 R-HSA-9612973 Autophagy 3 R-HSA-1430728 Metabolism 2 R-HSA-1640170 Cell Cycle 2 R-HSA-168256 Immune System 2 R-HSA-73894 DNA Repair 1
Partners
DYRK1AMYBMYOD1NUTM1RELASMAD1STAT3TP53
Complex memberships
STAT3–p300–Smad1 bridging complexSuper elongation complex (via AFF1 acetylation)p300–PCAF–MyoD coactivator complex

Evidence

Reading pass · 55 per-paper findings extracted from the source corpus
Year Finding Method Journal Conf PMIDs
1996 p300 and CBP possess intrinsic histone acetyltransferase (HAT) activity, acetylating all four core histones in nucleosomes, establishing them as a novel class of acetyltransferases lacking the conserved motif found in other acetyltransferases. In vitro acetyltransferase assay with recombinant p300/CBP and nucleosomal substrates Cell High 8945521
1994 p300 was molecularly cloned and characterized as a transcriptional adaptor protein; it contains a bromodomain and three cysteine/histidine-rich regions, with the C-terminal region binding adenoviral E1A; p300 can overcome E1A repression of the SV40 enhancer, functioning as a transcriptional coactivator. The EP300 gene was mapped to chromosome 22q13. cDNA cloning, domain mapping, functional reporter assays Genes & development High 7523245
1996 p300 associates with the estrogen receptor (ER) in an agonist-dependent manner and augments ligand-dependent transcriptional activation by ER; p300 is recruited as part of an ER coactivator complex involving ERAP160/SRC1, acting as a point of integration between ER and cAMP signaling pathways. Co-immunoprecipitation, ligand-dependent binding assays, transcriptional reporter assays Proceedings of the National Academy of Sciences of the United States of America Medium 8876171
1997 p300 directly acetylates p53 at its C-terminal regulatory domain (Lys-382), dramatically stimulating p53 sequence-specific DNA-binding activity, likely via acetylation-induced conformational change; this represents the first example of acetylation regulating a non-histone transcription factor. In vitro acetyltransferase assay, site-directed mutagenesis, electrophoretic mobility shift assay (EMSA), in vivo acetylation assay Cell High 9288740
1997 p300/CBP binds directly to p53 in the absence of viral oncoproteins; p300 and p53 colocalize in the nucleus and coexist in a stable DNA-binding complex; E1A disrupts this complex and suppresses p53-mediated activation of p21/bax promoters and p53-induced cell-cycle arrest and apoptosis. p300/CBP functions as a transcriptional adaptor for p53 in G1 checkpoint control. Co-immunoprecipitation, co-localization by immunofluorescence, reporter gene assays, cell-cycle analysis Nature High 9194565
1997 p300/CBP physically interact with Smads 1-4 (TGF-β pathway mediators); wild-type E1A, but not p300-binding-deficient E1A mutants, inhibits SMAD-dependent transcriptional responses to TGF-β and Smad4 MH2 domain intrinsic transactivation; overexpression of p300 enhances SMAD-dependent transactivation. Co-immunoprecipitation, E1A mutant epistasis, transcriptional reporter assays The Journal of biological chemistry High 9722503
1997 MyoD interacts directly with p300/CBP and PCAF, forming a multimeric complex on muscle promoter elements; p300 overexpression promotes p21 expression and terminal cell-cycle arrest, but this activity depends on PCAF's HAT activity rather than p300's. Viral transforming factors disrupt the complex without affecting MyoD-DNA interaction. Protein interaction assays (Co-IP, pulldown), reporter assays, antibody microinjection, cell differentiation assays Molecular cell High 9659901
1997 C/EBPβ interacts directly with p300; E1A inhibition of C/EBPβ-dependent transactivation requires E1A's p300-binding domain; the interaction maps to the E1A-binding region of p300 and the amino terminus of C/EBPβ; p300 mediates cooperation between C/EBPβ and Myb, revealing a scaffolding role for p300 in transcription factor synergy. Co-immunoprecipitation, pulldown assays, reporter gene assays with E1A mutants, dominant-negative inhibition Molecular and cellular biology High 9343424
1998 DNA damage triggers p53 acetylation in vivo at Lys-382 by p300, and at Lys-320 by PCAF; N-terminal phosphorylation of p53 (at Ser-33, Ser-37) directs C-terminal acetylation; this phosphorylation-acetylation cascade enhances p53 sequence-specific DNA binding and transcriptional activity. In vitro acetyltransferase assay, phospho-specific and acetyl-specific antibodies, UV/IR treatment of cells, mutagenesis Genes & development High 9744860
1999 p300 forms a physical and functional bridge between STAT3 and Smad1 in fetal brain; p300 interacts with STAT3 at its N-terminus (cytokine-independent) and with Smad1 at its C-terminus (cytokine-dependent); this STAT3-p300-Smad1 complex mediates cooperative LIF+BMP2 signaling to induce astrocyte differentiation from neural progenitors. Co-immunoprecipitation, domain mapping, cell-based differentiation assays Science High 10205054
1999 Smad1 interacts with p300 and CBP both in vitro and in vivo via two C-terminal interaction domains binding to a region near the C-terminus of p300/CBP; phosphorylation of Smad1 enhances CBP binding and further stimulates Smad1-dependent transcription; Smad1 N- and C-termini negatively interfere with p300/CBP binding. In vitro pulldown, co-immunoprecipitation, domain mapping, transcriptional reporter assays Biochimica et biophysica acta Medium 10673036
2000 p300/CBP physically associate with BRCA1 in a phosphorylation-independent manner; BRCA1 interacts with the CREB domain of p300/CBP via both its N- and C-termini; p300/CBP enhance BRCA1-mediated transactivation and this is suppressed by E1A; BRCA1 and p300 associate in a cell cycle-dependent manner by immunocolocalization. Co-immunoprecipitation, pulldown assays, reporter gene assays, immunofluorescence co-localization Proceedings of the National Academy of Sciences of the United States of America Medium 10655477
2000 p300/CBP acetylates MyoD at two lysines at the boundary of the DNA-binding domain; MyoD acetylation by CBP/p300 (and PCAF) increases its transcriptional activity on muscle-specific promoters; MyoD mutants that cannot be acetylated in vitro are not functionally activated. In vitro acetyltransferase assay, site-directed mutagenesis, microinjection functional assay The Journal of biological chemistry High 10944526
2000 EID-1, a novel Rb-binding protein, binds and inhibits p300's histone acetylase activity, thereby repressing MyoD-mediated skeletal muscle transcription in a manner potentiated by loss of EID-1's Rb binding; this defines p300 HAT activity as essential for MyoD coactivation. Yeast two-hybrid, Co-IP, HAT activity assay, reporter gene assays Molecular and cellular biology Medium 11073990
2000 Protein kinase C phosphorylates p300 at serine 89 in vivo; this phosphorylation event represses the transcriptional activity of p300, establishing a PKC-regulated signal transduction pathway for p300 function control. In vitro kinase assay, in vivo phosphorylation mapping, site-directed mutagenesis, transcriptional reporter assays The Journal of biological chemistry Medium 11020388
2001 CBP/p300 HAT activity is required for myogenic terminal differentiation (specifically cell fusion and muscle-specific gene expression) as demonstrated by chemical inhibition of CBP/p300 HAT activity and expression of a transdominant negative HAT mutant. Chemical HAT inhibitor, dominant-negative mutant expression, cell differentiation assays The EMBO journal High 11726517
2001 MEKK1 enhances p300-mediated transcription by activating multiple domains within p300; p300 is required for MEKK1-induced apoptosis; MEKK1-dependent activation of p300 may involve direct phosphorylation of p300 or non-JNK downstream kinases. Reporter gene assays, kinase assays, dominant-negative constructs, apoptosis assays The Journal of biological chemistry Medium 11278389
2001 NF-κB RelA subunit is acetylated by CBP/p300; acetylated RelA interacts weakly with IκBα; deacetylation by HDAC3 promotes IκBα binding and CRM1-dependent nuclear export, acting as a molecular switch controlling duration of NF-κB transcriptional response. In vitro acetylation assay, Co-IP, nuclear export assays, reporter gene assays Science High 11533489
2002 Phosphorylation status of nuclear NF-κB p65 determines its association with either CBP/p300 (phosphorylated p65, transcriptionally active) or HDAC-1 (unphosphorylated p50 homodimers, transcriptionally repressive); only p65 entering nucleus from cytoplasmic NF-κB:IκB complexes can activate transcription through CBP. Co-immunoprecipitation, reporter gene assays, chromatin fractionation Molecular cell High 11931769
2002 FIH-1 hydroxylates an asparagine residue within the HIF C-terminal transactivation domain under normoxia, blocking its association with p300; under hypoxia, loss of this hydroxylation allows the HIF CAD to interact with p300 and activate transcription. In vitro hydroxylase assay, Co-IP, reporter gene assays, mutagenesis Genes & development High 12080085
2002 Hydroxylation of a conserved asparagine in the HIF CAD under normoxia prevents interaction with p300; the Fe(II)/2-oxoglutarate-dependent dioxygenase inhibitors block this hydroxylation and constitutively allow HIF CAD-p300 interaction; Asn-to-Ala mutation results in constitutive p300 binding and strong transcriptional activity. Mutagenesis, in vitro hydroxylation, Co-IP with p300, reporter gene assays Science High 11823643
2005 Sox9 associates with p300 and other transcriptional cofactors; p300 potentiates Sox9-dependent transcription on chromatinized DNA in vitro, associated with histone hyperacetylation; HDAC inhibitor TSA stimulates Sox9-regulated cartilage matrix genes and induces histone acetylation at the Col2a1 enhancer. In vitro transcription on chromatinized templates, Co-IP, ChIP assay The Journal of biological chemistry Medium 16109717
2005 GCN5 and p300 functionally cooperate during early embryogenesis; GCN5(+/-)p300(+/-) double heterozygous mice show embryonic lethality with developmental stunting and increased apoptosis at E8.5, whereas PCAF(-/-)p300(+/-) mice are normal, demonstrating specific genetic interaction between GCN5 and p300. Genetic epistasis in mice (double-heterozygous knockouts), embryo phenotyping, apoptosis assay Developmental dynamics High 15937931
2006 ROCK2 is present in the nucleus, physically associates with p300 acetyltransferase in vitro and in cells, co-fractionates with p300 in large nuclear protein complexes, and phosphorylates p300 in vitro; nuclear-restricted constitutively active ROCK2 induces p300 phosphorylation in cells and increases p300 acetyltransferase activity in vitro. Co-immunoprecipitation, in vitro kinase assay, gel filtration, immunofluorescence, acetyltransferase activity assay The Journal of biological chemistry Medium 16574662
2008 A point mutation in p300 (Y630N, in the KIX domain) disrupts the interaction between p300 and c-Myb, leading to thrombocytosis and megakaryocyte expansion in mice; this establishes that the p300-c-Myb transcriptional regulatory complex plays an indispensable repressive role in megakaryocyte development. ENU mutagenesis screen, in vivo mouse genetic model, protein interaction assay, bone marrow transplantation Blood High 18684867
2009 p300 and CBP function as cytoplasmic E4 polyubiquitin ligases for p53; their ubiquitin ligase activities are exclusively cytoplasmic (absent from nuclear extracts); CBP deficiency specifically stabilizes cytoplasmic but not nuclear p53; the N-terminal ~616 aa of CBP (including the C/H1-TAZ1 domain) is sufficient for E4 activity and intrinsic E3 autoubiquitination. Cell fractionation, in vitro ubiquitin ligase assay, domain deletion analysis, p300/CBP-deficient cell analysis Proceedings of the National Academy of Sciences of the United States of America High 19805293
2009 IL-4 increases CBP/p300 expression and enhances AR-CBP/p300 interaction, recruiting CBP/p300 to androgen-responsive element promoters; p300/CBP acetylates AR in response to IL-4; siRNA knockdown of CBP/p300 abolishes IL-4-mediated AR activation and AR acetylation. Western blot, Co-immunoprecipitation, ChIP assay, siRNA knockdown, reporter assays The Prostate Medium 18819102
2009 Plumbagin (RTK1) inhibits p300 HAT activity in a non-competitive manner in vivo; it specifically inhibits p300-mediated acetylation of p53 but not PCAF-mediated acetylation; site-directed mutagenesis and docking studies show a hydrogen bond between the hydroxyl group of plumbagin and Lys-1358 in the p300 HAT domain. In vitro acetyltransferase assay, site-directed mutagenesis, docking studies, in vivo acetylation assay The Journal of biological chemistry Medium 19570987
2010 p300 acetylates tau protein, preventing its degradation; inhibition of p300 with a small molecule promotes tau deacetylation and eliminates pathogenic p-tau; SIRT1 deacetylates tau and its deletion enhances acetylated-tau and p-tau accumulation. In vitro acetyltransferase assay, acetyl-specific antibodies, p300 inhibitor treatment, SIRT1 knockout cells Neuron High 20869593
2011 Beta-HPV E6 proteins (types 5 and 8) directly interact with p300, blocking the AKT-p300 association; since AKT association is necessary for p300 stability, this leads to proteasomal degradation of p300 in an E6AP-independent manner, with downstream effects on differentiation markers K1, K10, and Involucrin. Co-immunoprecipitation, proteasome inhibitor assays, protein stability assays, knockdown experiments PLoS pathogens Medium 21901101
2014 CBP, and less efficiently p300, acetylates PCNA at Lys13, 14, 77, and 80 to promote removal of chromatin-bound PCNA and its proteasomal degradation during nucleotide excision repair (NER); mutation of these residues impairs DNA replication and repair, enhances UV sensitivity, and prevents proteolytic degradation of PCNA after DNA damage. In vitro acetyltransferase assay, site-directed mutagenesis, protein stability assays, DNA repair assays, UV sensitivity assays Nucleic acids research High 24939902
2014 BAG6 regulates nuclear localization of EP300/p300; in the absence of BAG6, EP300 accumulates in the cytoplasm; BAG6 interaction with EP300 occurs in the cytoplasm and promotes nuclear translocation of EP300 during starvation; this controls EP300-dependent acetylation of p53 (nuclear) and ATG proteins (cytoplasmic), thereby regulating autophagy. Immunofluorescence, cell fractionation, Co-IP, acetylation assays, autophagy assays in bag6-/- MEFs Autophagy Medium 24852146
2015 p300 catalyzes histone crotonylation in addition to acetylation; p300-catalyzed histone crotonylation directly stimulates transcription to a greater degree than histone acetylation; cellular concentrations of crotonyl-CoA regulate histone crotonylation levels and corresponding gene expression. In vitro acetyltransferase/crotonyltransferase assay, metabolic perturbation, gene expression analysis, ChIP-seq Molecular cell High 25818647
2015 p300 interacts with and acetylates RORγt at Lys81; p300 knockdown downregulates RORγt protein and RORγt-mediated gene expression in Th17 cells; HDAC1 reciprocally interacts with RORγt and reduces its acetylation level, antagonizing p300's effect on IL-17 transcription. Co-immunoprecipitation, in vitro acetyltransferase assay, RNAi knockdown, reporter assays Scientific reports Medium 26549310
2015 DDX24 interacts with p300, suppressing p300-mediated acetylation of p53; DDX24 knockdown increases p53 acetylation and p53 transcriptional target (p21, PUMA) activation; DDX24 overexpression inhibits p300-p53 interaction; DDX24 knockdown induces p53-dependent cell cycle arrest and senescence. Co-immunoprecipitation, acetylation assays, RNAi knockdown, cell cycle analysis Oncogene Medium 25867071
2016 p300 deletion (but not CBP deletion) markedly accelerates leukemogenesis in NHD13 MDS mouse models; loss of p300 restores HSPC self-renewal, promotes symmetric self-renewal divisions, decreases apoptosis, and enhances MAPK and JAK/STAT pathway activation, establishing a specific tumor-suppressor role for p300 distinct from CBP. Conditional knockout mouse model, colony-forming assays, in vivo transplantation, pathway activation assays Leukemia High 27881875
2017 mTORC1 directly phosphorylates p300 at four serine residues in its C-terminal domain; this phosphorylation prevents the catalytic HAT domain from binding the RING domain, eliminating intramolecular autoinhibition; mTORC1-dependent p300 activation suppresses starvation-induced autophagy and activates lipogenesis. In vitro kinase assay, domain interaction assay, mutagenesis, co-immunoprecipitation, autophagy and lipogenesis assays Molecular cell High 29033323
2017 p300 functions as a lysine 2-hydroxyisobutyryltransferase (Khib), differentially targeting Khib and Kac on distinct lysine sites (only 6 of 149 p300-targeted Khib sites overlap with 693 Kac sites); p300-mediated Khib targets glycolytic enzymes including ENO1; p300 deletion reduces Khib on these sites, decreasing glycolytic enzyme activity, impairing glycolysis, and causing hypersensitivity to glucose-depletion-induced cell death. Proteomics, in vitro acetyltransferase assay with 2-hydroxyisobutyryl-CoA, p300 knockout cells, enzymatic activity assay Molecular cell High 29775581
2018 Transcription factor dimerization (IRF3 and STAT1 as models) enables trans-autoacetylation of p300 in a highly conserved intrinsically disordered autoinhibitory lysine-rich loop, activating p300; crystal structure of p300 shows the autoinhibitory loop invading the active site of a neighboring HAT domain (snapshot of trans-autoacetylation intermediate); substrate access involves rearrangement of an autoinhibitory RING domain. Crystal structure determination, in vitro autoacetylation assay, mutagenesis, transcription factor dimerization assay Nature High 30323286
2018 DYRK1A interacts with p300 and CBP (identified by proteomics); DYRK1A overexpression causes hyperphosphorylation of p300/CBP; DYRK1A co-localizes with p300/CBP at enhancers genome-wide; DYRK1A knockdown causes significant loss of H3K27ac at enhancers, suggesting DYRK1A modulates p300/CBP activity at enhancers. Proteomics (affinity purification-MS), Co-IP, ChIP-seq, shRNA knockdown, histone modification analysis Nucleic acids research Medium 30137413
2019 p300 acetylates AFF1 (a super elongation complex subunit) at a specific site in response to genotoxic stress; AFF1 acetylation reduces its interaction with other SEC components and impairs P-TEFb-mediated CTD phosphorylation of RNA Pol II in vitro and in vivo; reexpression of wild-type but not acetylation-mimic AFF1 restores SEC assembly and target gene expression; p300-mediated AFF1 acetylation is dynamic and correlates with global transcriptional downregulation during genotoxic stress. In vitro acetyltransferase assay, site-specific mutagenesis, Co-IP, reporter gene assays, genotoxic stress cellular assays Proceedings of the National Academy of Sciences of the United States of America High 31611376
2019 EP300 controls enhancer acetylation in germinal center B cells through distinct transcriptional programs from CREBBP; deletion of Ep300 but not Crebbp impairs GC B cell fitness in vivo; combined loss of Crebbp and Ep300 completely abrogates GC formation; CREBBP-mutant DLBCL cells show synthetic lethality with EP300 inhibition. Conditional knockout mouse models, ChIP-seq, B cell functional assays, pharmacological inhibition Immunity High 31519498
2019 p300 acetylates HPV E2 at K111, and this acetylation is required for recruitment of Topoisomerase 1 to the viral origin and for viral DNA replication; higher levels of P300 (but not CBP) enhance replication with wild-type E2 but not acetylation-defective K111R mutant. Functional replication assay, mutagenesis, topoisomerase recruitment assay Journal of virology Medium 30651357
2020 p300 physically interacts with NRF2 and interferes with NRF2-KEAP1 complex formation, increasing NRF2 protein abundance, stability, and nuclear localization; the acetyltransferase activity of p300 is indispensable for these stabilizing effects; p300 overexpression protects cells from oxidative stress. Co-immunoprecipitation, protein stability assays, localization experiments, acetyltransferase mutant analysis, cell viability assay Biochemical and biophysical research communications Medium 32057361
2020 p300 is the predominant H3K27 acetyltransferase in mouse embryonic stem cells; loss of p300 has greater effect on enhancer acetylation than promoter acetylation; distinct gene sets are transcriptionally dysregulated by p300 vs. CBP depletion; p300 depletion stabilizes p53 pathway targets in mESCs. ChIP-seq, ATAC-seq, RNA-seq after p300/CBP knockdown in mESCs BMC molecular and cell biology Medium 32690000
2021 Short-chain fatty acids propionate and butyrate are converted to their corresponding acyl-CoAs which are used by p300 to catalyze auto-acylation of the autoinhibitory loop, activating p300 for histone/protein acetylation; this mechanism (not HDAC inhibition) accounts for the hyperacetylation induced by these SCFAs. Quantitative proteomics of histone modifications, in vitro acetyltransferase assay, metabolic labeling eLife High 34677127
2022 EP300 controls the enhancer landscape in MYCN-amplified neuroblastoma by interacting with TFAP2β (a CRC transcription factor), while CBP has a limited role; a PROTAC degrader JQAD1 selectively targets EP300 for CRBN-dependent degradation, causing loss of H3K27ac at CRC enhancers and neuroblastoma apoptosis. ChIP-seq, PROTAC-mediated degradation, Co-IP, cell viability assays, in vivo tumor models Cancer discovery High 34772733
2022 NUT contains an acidic transcriptional activation domain that binds the TAZ2 domain of p300; NUT-TAZ2 interaction allosterically activates p300 by relieving TAZ2 autoinhibition; cancer mutations interfering with TAZ2 autoinhibition also allosterically activate p300; p300 activation drives acetylation-dependent feed-forward chromatin interactions via bromodomain multivalent acetyl-lysine binding. NMR structure, Co-IP, mutagenesis, acetyltransferase activity assay, ChIP-seq Nature communications High 36522330
2022 EP300 KIX domain interaction with transcription factors (including MYB) determines its pro-tumorigenic activity in SCLC; Ala627 in EP300 KIX confers higher protein-binding affinity than the equivalent Asp647 in CREBBP KIX, providing molecular basis for EP300-specific KIX-binding partner selectivity; EP300 mutants lacking the acetyltransferase domain accelerate SCLC but complete Ep300 knockout suppresses SCLC. Mouse SCLC models, domain deletion analysis, binding affinity measurements, KIX domain blockade Science advances High 35171684
2023 Cryo-EM structures of p300/CBP bound to nucleosomes show that p300/CBP recognizes H4 N-terminal tail acetylation (H4NTac) via its bromodomain and contacts DNA minor grooves outside the bromodomain pocket; this directs the catalytic center to non-H4 histone NTs; p300 primarily writes H2BNT acetylation by reading H4NTac, and H2BNTac promotes H2A-H2B dissociation from the nucleosome; p300/CBP can replicate H3-H4 tetramer acetylation epigenetically. Cryo-EM structure determination, in vitro acetyltransferase assay, nucleosome remodeling assay Nature communications High 37460559
2023 p300 chromatin-binding in live cells depends entirely on combinatorial binding of multiple TF-interaction domains; acetyltransferase activity opposes p300-chromatin association; N-terminal TF-interaction domains regulate acetyltransferase activity; single TF-interaction domains are insufficient for chromatin binding, implying p300 requires multiple simultaneous TF inputs. Single-molecule tracking in live cells, systematic domain mutagenesis, chromatin binding assays Molecular cell High 38159566
2023 HDAC8 deacetylates EP300, causing its enzymatic inactivation; HDAC8-mediated EP300 inactivation increases H3K27ac and chromatin accessibility at c-Jun binding sites while decreasing binding at MITF sites, driving a neural crest-stem cell transcriptional state and invasive phenotype promoting melanoma brain metastasis. ATAC-seq, ChIP-seq, HDAC8 inhibitor/knockout, EP300 acetylation assay Nature communications High 38030596
2023 EP300 facilitates human trophoblast differentiation specifically (not CREBBP); EP300 knockdown but not CREBBP knockdown inhibits TSC differentiation into EVT and STB lineages; EP300 knockdown strongly upregulates TGF-α/EGFR signaling, suggesting EP300 facilitates differentiation by suppressing EGFR signaling. RNAi knockdown, CRISPR/Cas9 mutagenesis, trophoblast organoid differentiation assays, RNA-seq Proceedings of the National Academy of Sciences of the United States of America Medium 37406095
2024 p300 nucleus-to-cytoplasm shuttling regulates mTORC1 activity in response to nutrient levels; nutrient depletion triggers AMPK-dependent phosphorylation of p300 at Ser89, causing cytoplasm-to-nucleus relocalization and decreased acetylation of raptor (mTORC1 component), reducing mTORC1 activity and activating autophagy; nutrient readdition causes PP2A-dependent dephosphorylation of nuclear p300 enabling CRM1-dependent nuclear export and mTORC1 reactivation; in Hutchinson-Gilford progeria, progerin mislocalizes p300 causing mTORC1 hyperactivation and defective autophagy. Live-cell imaging, cell fractionation, kinase/phosphatase assays, mTORC1 activity assays, AMPK/PP2A inhibitor experiments, CRM1 inhibition, progeria patient cells Nature cell biology High 38267537
2024 P300 functions as a histone crotonylation writer during embryonic development; P300 depletion causes developmental defects and transcriptomic dysregulation in embryos; H3K18 crotonylation (H3K18cr) is primarily localized at active promoters and serves as a distinctive epigenetic indicator of transcriptional activation during preimplantation development. P300 depletion in embryos, transcriptome analysis, ChIP-seq for H3K18cr, in vitro crotonyltransferase assay Nature communications High 39080296

Source papers

Stage 0 corpus · 130 papers · ranked by NIH iCite citations
Year Title Journal Citations PMID
2014 Biological insights from 108 schizophrenia-associated genetic loci. Nature 5878 25056061
2019 Metabolic regulation of gene expression by histone lactylation. Nature 3090 31645732
1996 The transcriptional coactivators p300 and CBP are histone acetyltransferases. Cell 2464 8945521
1997 Characterization of a 3-phosphoinositide-dependent protein kinase which phosphorylates and activates protein kinase Balpha. Current biology : CB 2434 9094314
1997 Activation of p53 sequence-specific DNA binding by acetylation of the p53 C-terminal domain. Cell 2223 9288740
2005 A human protein-protein interaction network: a resource for annotating the proteome. Cell 1704 16169070
2002 Raptor, a binding partner of target of rapamycin (TOR), mediates TOR action. Cell 1482 12150926
2002 Generation and initial analysis of more than 15,000 full-length human and mouse cDNA sequences. Proceedings of the National Academy of Sciences of the United States of America 1479 12477932
1996 A p300/CBP-associated factor that competes with the adenoviral oncoprotein E1A. Nature 1299 8684459
2006 Substrate and functional diversity of lysine acetylation revealed by a proteomics survey. Molecular cell 1260 16916647
1997 Nuclear receptor coactivator ACTR is a novel histone acetyltransferase and forms a multimeric activation complex with P/CAF and CBP/p300. Cell 1255 9267036
2002 FIH-1 is an asparaginyl hydroxylase enzyme that regulates the transcriptional activity of hypoxia-inducible factor. Genes & development 1253 12080085
2002 Asparagine hydroxylation of the HIF transactivation domain a hypoxic switch. Science (New York, N.Y.) 1247 11823643
2011 Pyruvate kinase M2 is a PHD3-stimulated coactivator for hypoxia-inducible factor 1. Cell 1209 21620138
2015 The BioPlex Network: A Systematic Exploration of the Human Interactome. Cell 1118 26186194
2017 Architecture of the human interactome defines protein communities and disease networks. Nature 1085 28514442
2001 Duration of nuclear NF-kappaB action regulated by reversible acetylation. Science (New York, N.Y.) 1046 11533489
1998 DNA damage activates p53 through a phosphorylation-acetylation cascade. Genes & development 1035 9744860
2015 A human interactome in three quantitative dimensions organized by stoichiometries and abundances. Cell 1015 26496610
1994 Molecular cloning and functional analysis of the adenovirus E1A-associated 300-kD protein (p300) reveals a protein with properties of a transcriptional adaptor. Genes & development 955 7523245
1994 Association and activation of Jak-Tyk kinases by CNTF-LIF-OSM-IL-6 beta receptor components. Science (New York, N.Y.) 929 8272873
2001 p300/CBP proteins: HATs for transcriptional bridges and scaffolds. Journal of cell science 894 11559745
2018 VIRMA mediates preferential m6A mRNA methylation in 3'UTR and near stop codon and associates with alternative polyadenylation. Cell discovery 829 29507755
2008 Induced ncRNAs allosterically modify RNA-binding proteins in cis to inhibit transcription. Nature 807 18509338
2002 The phosphorylation status of nuclear NF-kappa B determines its association with CBP/p300 or HDAC-1. Molecular cell 795 11931769
2008 Global analysis of host-pathogen interactions that regulate early-stage HIV-1 replication. Cell 787 18854154
2010 Acetylation of tau inhibits its degradation and contributes to tauopathy. Neuron 756 20869593
2011 Inactivating mutations of acetyltransferase genes in B-cell lymphoma. Nature 742 21390126
1999 Synergistic signaling in fetal brain by STAT3-Smad1 complex bridged by p300. Science (New York, N.Y.) 722 10205054
2017 Roles of tau protein in health and disease. Acta neuropathologica 716 28386764
2021 Dual proteome-scale networks reveal cell-specific remodeling of the human interactome. Cell 705 33961781
1997 Binding and modulation of p53 by p300/CBP coactivators. Nature 619 9194565
2004 p300/CBP and cancer. Oncogene 519 15156177
2015 Intracellular crotonyl-CoA stimulates transcription through p300-catalyzed histone crotonylation. Molecular cell 488 25818647
2004 CBP and p300: HATs for different occasions. Biochemical pharmacology 382 15313412
1997 Differential roles of p300 and PCAF acetyltransferases in muscle differentiation. Molecular cell 371 9659901
1998 Conjunction dysfunction: CBP/p300 in human disease. Trends in genetics : TIG 343 9613201
1996 p300 is a component of an estrogen receptor coactivator complex. Proceedings of the National Academy of Sciences of the United States of America 336 8876171
1997 Interaction and functional collaboration of p300 and C/EBPbeta. Molecular and cellular biology 314 9343424
1998 Physical and functional interaction of SMADs and p300/CBP. The Journal of biological chemistry 285 9722503
1999 p300 and CBP: partners for life and death. Journal of cellular physiology 240 10497301
2021 Targeting the p300/CBP Axis in Lethal Prostate Cancer. Cancer discovery 231 33431496
2022 Histone acetyltransferases CBP/p300 in tumorigenesis and CBP/p300 inhibitors as promising novel anticancer agents. Theranostics 192 35836809
2000 CBP/p300 interact with and function as transcriptional coactivators of BRCA1. Proceedings of the National Academy of Sciences of the United States of America 179 10655477
2017 Exploitation of EP300 and CREBBP Lysine Acetyltransferases by Cancer. Cold Spring Harbor perspectives in medicine 174 27881443
2011 Quercetin suppresses cyclooxygenase-2 expression and angiogenesis through inactivation of P300 signaling. PloS one 168 21857970
2018 p300-Mediated Lysine 2-Hydroxyisobutyrylation Regulates Glycolysis. Molecular cell 154 29775581
2007 The transcriptional coactivator and acetyltransferase p300 in fibroblast biology and fibrosis. Journal of cellular physiology 154 17559085
2018 Transcription factor dimerization activates the p300 acetyltransferase. Nature 142 30323286
2017 mTORC1 Phosphorylates Acetyltransferase p300 to Regulate Autophagy and Lipogenesis. Molecular cell 139 29033323
2022 EP300 Selectively Controls the Enhancer Landscape of MYCN-Amplified Neuroblastoma. Cancer discovery 133 34772733
2021 Targeted degradation of the enhancer lysine acetyltransferases CBP and p300. Cell chemical biology 132 33400925
2005 Sox9 and p300 cooperatively regulate chromatin-mediated transcription. The Journal of biological chemistry 129 16109717
2007 Expression of HDAC1 and CBP/p300 in human colorectal carcinomas. Journal of clinical pathology 124 17720775
2009 CBP and p300 are cytoplasmic E4 polyubiquitin ligases for p53. Proceedings of the National Academy of Sciences of the United States of America 123 19805293
2019 Unique and Shared Epigenetic Programs of the CREBBP and EP300 Acetyltransferases in Germinal Center B Cells Reveal Targetable Dependencies in Lymphoma. Immunity 114 31519498
2021 Short-chain fatty acids activate acetyltransferase p300. eLife 107 34677127
2019 Brd4 and P300 Confer Transcriptional Competency during Zygotic Genome Activation. Developmental cell 107 31211993
2000 CREB-binding protein/p300 activates MyoD by acetylation. The Journal of biological chemistry 106 10944526
2000 A novel Rb- and p300-binding protein inhibits transactivation by MyoD. Molecular and cellular biology 105 11073990
2009 Inhibition of lysine acetyltransferase KAT3B/p300 activity by a naturally occurring hydroxynaphthoquinone, plumbagin. The Journal of biological chemistry 102 19570987
2001 CBP/p300 and muscle differentiation: no HAT, no muscle. The EMBO journal 102 11726517
2000 Phosphorylation of p300 at serine 89 by protein kinase C. The Journal of biological chemistry 102 11020388
1996 p300 and CBP as transcriptional regulators and targets of oncogenic events. Biological chemistry 101 8960368
2023 LPCAT3 Is Transcriptionally Regulated by YAP/ZEB/EP300 and Collaborates with ACSL4 and YAP to Determine Ferroptosis Sensitivity. Antioxidants & redox signaling 90 37166352
2023 Therapeutic targeting of EP300/CBP by bromodomain inhibition in hematologic malignancies. Cancer cell 88 37995682
2006 Nuclear Rho kinase, ROCK2, targets p300 acetyltransferase. The Journal of biological chemistry 88 16574662
2014 CBP and p300 acetylate PCNA to link its degradation with nucleotide excision repair synthesis. Nucleic acids research 85 24939902
2011 Beta-HPV 5 and 8 E6 promote p300 degradation by blocking AKT/p300 association. PLoS pathogens 81 21901101
2023 METTL14 regulates microglia/macrophage polarization and NLRP3 inflammasome activation after ischemic stroke by the KAT3B-STING axis. Neurobiology of disease 79 37541353
2019 Bromodomain inhibition of the coactivators CBP/EP300 facilitate cellular reprogramming. Nature chemical biology 76 30962627
2023 The Role of CREBBP/EP300 and Its Therapeutic Implications in Hematological Malignancies. Cancers 70 36831561
2016 Regulatory T Cell Modulation by CBP/EP300 Bromodomain Inhibition. The Journal of biological chemistry 69 27056325
2002 Mutation analysis of EP300 in colon, breast and ovarian carcinomas. International journal of cancer 63 12385008
2020 Antitumor activity of the dual BET and CBP/EP300 inhibitor NEO2734. Blood advances 61 32882003
2020 Differential contribution of p300 and CBP to regulatory element acetylation in mESCs. BMC molecular and cell biology 57 32690000
2023 Epigenetic mechanisms to propagate histone acetylation by p300/CBP. Nature communications 56 37460559
2018 Modulating the masters: chemical tools to dissect CBP and p300 function. Current opinion in chemical biology 55 30025258
2015 Reciprocal regulation of RORγt acetylation and function by p300 and HDAC1. Scientific reports 53 26549310
2020 The acetyltransferase p300 regulates NRF2 stability and localization. Biochemical and biophysical research communications 51 32057361
1999 Activation of Smad1-mediated transcription by p300/CBP. Biochimica et biophysica acta 50 10673036
2023 Lactate-induced histone lactylation by p300 promotes osteoblast differentiation. PloS one 49 38051708
2022 Structural insights into p300 regulation and acetylation-dependent genome organisation. Nature communications 49 36522330
2020 p300 in Cardiac Development and Accelerated Cardiac Aging. Aging and disease 49 32765954
2019 MITF Expression Predicts Therapeutic Vulnerability to p300 Inhibition in Human Melanoma. Cancer research 49 30910803
2001 Stimulation of p300-mediated transcription by the kinase MEKK1. The Journal of biological chemistry 49 11278389
2017 Mapping cell type-specific transcriptional enhancers using high affinity, lineage-specific Ep300 bioChIP-seq. eLife 48 28121289
2017 ZEB1 Mediates Drug Resistance and EMT in p300-Deficient CRC. Journal of Cancer 48 28638460
2016 Development of Selective CBP/P300 Benzoxazepine Bromodomain Inhibitors. Journal of medicinal chemistry 48 27673482
2023 p300 is an obligate integrator of combinatorial transcription factor inputs. Molecular cell 43 38159566
2015 Negative regulation of the p300-p53 interplay by DDX24. Oncogene 41 25867071
2003 Inhibition of p300/CBP by early B-cell factor. Molecular and cellular biology 41 12748286
2015 High-density P300 enhancers control cell state transitions. BMC genomics 40 26546038
2020 CARM1 inhibition reduces histone acetyltransferase activity causing synthetic lethality in CREBBP/EP300-mutated lymphomas. Leukemia 38 32576962
2018 Inhibition of EP300 and DDR1 synergistically alleviates pulmonary fibrosis in vitro and in vivo. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie 38 30119248
2002 Acetyltransferase machinery conserved in p300/CBP-family proteins. Oncogene 38 11948408
2000 Viral replication and the coactivators p300 and CBP. Trends in microbiology 38 11115752
2014 BAG6/BAT3 modulates autophagy by affecting EP300/p300 intracellular localization. Autophagy 37 24852146
2023 EGR1 induces EMT in pancreatic cancer via a P300/SNAI2 pathway. Journal of translational medicine 35 36932397
2019 EP300 and SIRT1/6 Co-Regulate Lapatinib Sensitivity Via Modulating FOXO3-Acetylation and Activity in Breast Cancer. Cancers 34 31357743
2016 Loss of p300 accelerates MDS-associated leukemogenesis. Leukemia 34 27881875
2018 DYRK1A interacts with histone acetyl transferase p300 and CBP and localizes to enhancers. Nucleic acids research 32 30137413
2022 KIX domain determines a selective tumor-promoting role for EP300 and its vulnerability in small cell lung cancer. Science advances 30 35171684
2015 The LIM protein Ajuba promotes adipogenesis by enhancing PPARγ and p300/CBP interaction. Cell death and differentiation 30 26113042
2023 Cardiac Aging Is Promoted by Pseudohypoxia Increasing p300-Induced Glycolysis. Circulation research 29 37681309
2008 Point mutation in the gene encoding p300 suppresses thrombocytopenia in Mpl-/- mice. Blood 29 18684867
2017 Downregulation of decidual SP1 and P300 is associated with severe preeclampsia. Journal of molecular endocrinology 28 29273682
2010 p300- and Myc-mediated regulation of glioblastoma multiforme cell differentiation. Oncotarget 28 21304179
1999 The coactivators p300 and CBP have different functions during the differentiation of F9 cells. Journal of molecular medicine (Berlin, Germany) 28 10475063
2024 p300 nucleocytoplasmic shuttling underlies mTORC1 hyperactivation in Hutchinson-Gilford progeria syndrome. Nature cell biology 27 38267537
2014 Naphthoquinone-mediated inhibition of lysine acetyltransferase KAT3B/p300, basis for non-toxic inhibitor synthesis. The Journal of biological chemistry 27 24469461
2005 GCN5 and p300 share essential functions during early embryogenesis. Developmental dynamics : an official publication of the American Association of Anatomists 26 15937931
2020 p300 is upregulated by docetaxel and is a target in chemoresistant prostate cancer. Endocrine-related cancer 25 31951590
2016 CBP/p300 acetyltransferases regulate the expression of NKG2D ligands on tumor cells. Oncogene 25 27477692
2014 p300 cooperates with c-Jun and PARP-1 at the p300 binding site to activate RhoB transcription in NSC126188-mediated apoptosis. Biochimica et biophysica acta 25 24636898
2023 HDAC8-mediated inhibition of EP300 drives a transcriptional state that increases melanoma brain metastasis. Nature communications 24 38030596
2018 Epstein-Barr Virus Nuclear Antigen Leader Protein Coactivates EP300. Journal of virology 24 29467311
2009 Interleukin-4 activates androgen receptor through CBP/p300. The Prostate 24 18819102
2023 EP300 facilitates human trophoblast stem cell differentiation. Proceedings of the National Academy of Sciences of the United States of America 23 37406095
2018 Enhancer RNA and NFκB-dependent P300 regulation of ADAMDEC1. Molecular immunology 23 30352365
2018 EP300-HDAC1-SWI/SNF functional unit defines transcription of some DNA repair enzymes during differentiation of human macrophages. Biochimica et biophysica acta. Gene regulatory mechanisms 23 30414852
2019 Acetylation of E2 by P300 Mediates Topoisomerase Entry at the Papillomavirus Replicon. Journal of virology 21 30651357
2024 Genetic dysregulation of EP300 in cancers in light of cancer epigenome control - targeting of p300-proficient and -deficient cancers. Molecular therapy. Oncology 20 39351073
2023 PPARα Senses Bisphenol S to Trigger EP300-Mediated Autophagy Blockage and Hepatic Steatosis. Environmental science & technology 19 38085933
2022 TWIST1-EP300 Expedites Gastric Cancer Cell Resistance to Apatinib by Activating the Expression of COL1A2. Analytical cellular pathology (Amsterdam) 19 35242497
2021 Targeting the p300/NONO axis sensitizes melanoma cells to BRAF inhibitors. Oncogene 19 34017080
2020 A Novel E2F1-EP300-VMP1 Pathway Mediates Gemcitabine-Induced Autophagy in Pancreatic Cancer Cells Carrying Oncogenic KRAS. Frontiers in endocrinology 19 32655498
2024 P300 regulates histone crotonylation and preimplantation embryo development. Nature communications 18 39080296
2019 AFF1 acetylation by p300 temporally inhibits transcription during genotoxic stress response. Proceedings of the National Academy of Sciences of the United States of America 18 31611376
2019 Coordinated expression of p300 and HDAC3 upregulates histone acetylation during dentinogenesis. Journal of cellular biochemistry 18 31692090